

Sabrina Giammarco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3057292/publications.pdf>

Version: 2024-02-01

30
papers

603
citations

623699

14
h-index

610883

24
g-index

32
all docs

32
docs citations

32
times ranked

1141
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. <i>Clinical Infectious Diseases</i> , 2017, 65, 1884-1896.	5.8	103
2	Peripherally inserted central catheters (PICCs) in the management of oncohematological patients submitted to autologous stem cell transplantation. <i>Supportive Care in Cancer</i> , 2013, 21, 531-535.	2.2	50
3	Hyperleukocytosis and leukostasis: management of a medical emergency. <i>Expert Review of Hematology</i> , 2017, 10, 147-154.	2.2	49
4	Bone marrow transplantation versus immunosuppressive therapy in patients with acquired severe aplastic anemia. <i>International Journal of Hematology</i> , 2016, 104, 168-174.	1.6	46
5	Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved?. <i>Blood</i> , 2018, 131, 1989-1992.	1.4	43
6	The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 691-696.	2.3	40
7	First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated 2001-2012. <i>American Journal of Hematology</i> , 2018, 93, 643-648.	4.1	32
8	Use of eltrombopag in aplastic anemia in Europe. <i>Annals of Hematology</i> , 2019, 98, 1341-1350.	1.8	30
9	Role of fecal calprotectin as biomarker of gastrointestinal GVHD after allogeneic stem cell transplantation. <i>Blood</i> , 2012, 120, 4443-4444.	1.4	22
10	Graft versus host disease in unmanipulated haploidentical marrow transplantation with a modified post-transplant cyclophosphamide (PT-CY) regimen: an update on 425 patients. <i>Bone Marrow Transplantation</i> , 2019, 54, 708-712.	2.4	22
11	Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogeneic stem cell transplantation. <i>Leukemia Research</i> , 2011, 35, 422-423.	0.8	19
12	Haploidentical donor transplants for severe aplastic anemia. <i>Seminars in Hematology</i> , 2019, 56, 190-193.	3.4	19
13	Salivary Proteomic Analysis and Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 888-892.	2.0	17
14	Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study. <i>International Journal of Hematology</i> , 2021, 114, 228-234.	1.6	16
15	Second haploidentical stem cell transplantation for primary graft failure. <i>Bone Marrow Transplantation</i> , 2021, 56, 1291-1296.	2.4	14
16	Fecal but not serum calprotectin is a potential marker of GVHD after stem cell transplantation. <i>Annals of Hematology</i> , 2017, 96, 929-933.	1.8	10
17	Unrelated cord blood transplantation and post-transplant cyclophosphamide. <i>Haematologica</i> , 2019, 104, e77-e78.	3.5	10
18	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THERAPY-RELATED MYELOID NEOPLASMS (t-MN) OF THE ADULT: MONOCENTRIC OBSERVATIONAL STUDY AND REVIEW OF THE LITERATURE.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2017, 10, 2018005.	1.3	9

#	ARTICLE	IF	CITATIONS
19	Gut Microbiome Changes after Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 1953-1953.	1.4	9
20	Androgens MAY BOOST Hematologic Response to ANTI-Thymocyte Globulin in Acquired Aplastic Anemia. <i>Blood</i> , 2016, 128, 3900-3900.	1.4	9
21	Extreme thrombocytosis in chronic myeloid leukemia in the era of tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , 2014, 55, 2958-2960.	1.3	7
22	Efficacy and Tolerability of First Line Arsenic Trioxide in Combination With All-Trans Retinoic Acid in Patients With Acute Promyelocytic Leukemia: Real Life Experience. <i>Frontiers in Oncology</i> , 2021, 11, 614721.	2.8	6
23	Methylenetetrahydrofolate reductase polymorphisms in myelodysplastic syndromes and therapy-related myeloid neoplasms. <i>Leukemia and Lymphoma</i> , 2014, 55, 2942-2944.	1.3	4
24	Massive pulmonary embolism at the onset of acute promyelocytic leukemia. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 8, 2016027.	1.3	4
25	Changes in protein serum levels during stem cell transplantation. <i>European Journal of Clinical Investigation</i> , 2017, 47, 711-718.	3.4	3
26	Sudden death of a SARS-CoV-2 patient with NPM1+ acute myeloid leukemia mimicking acute promyelocytic leukemia. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 341-342.	1.3	3
27	Allogeneic Transplant for Mycosis Fungoides in Patient with Wiskott-Aldrich Syndrome. <i>Journal of Clinical Immunology</i> , 2018, 38, 7-9.	3.8	2
28	Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid. <i>Leukemia and Lymphoma</i> , 2019, 60, 1328-1330.	1.3	2
29	Stem cell transplantation in aplastic anemia: Impact on choices for first line therapy. <i>HemaSphere</i> , 2019, 3, 15-17.	2.7	0
30	ROLE of Fecal Calprotectin as BIOMARKER of Gvhd AFTER Allogeneic STEM CELL TRANSPLANTATION. <i>Blood</i> , 2010, 116, 1253-1253.	1.4	0